Asset Management One Co. Ltd. Buys Shares of 989 Blueprint Medicines Co. (NASDAQ:BPMC)

Asset Management One Co. Ltd. bought a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 989 shares of the biotechnology company’s stock, valued at approximately $88,000.

A number of other large investors have also recently bought and sold shares of the stock. Pallas Capital Advisors LLC lifted its stake in shares of Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock worth $523,000 after purchasing an additional 176 shares during the period. Franklin Resources Inc. lifted its stake in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after purchasing an additional 265 shares during the period. Quarry LP purchased a new position in shares of Blueprint Medicines during the 3rd quarter worth $32,000. Van ECK Associates Corp lifted its stake in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 363 shares during the period. Finally, Covestor Ltd lifted its stake in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares during the period.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the completion of the sale, the chief operating officer now directly owns 71,657 shares in the company, valued at $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,851 shares of company stock valued at $4,984,696 over the last three months. 4.21% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BPMC shares. Piper Sandler increased their price target on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. JPMorgan Chase & Co. increased their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Wells Fargo & Company cut their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $123.83.

Blueprint Medicines Trading Down 2.2 %

Shares of BPMC opened at $92.25 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock has a market cap of $5.90 billion, a PE ratio of -85.42 and a beta of 0.62. Blueprint Medicines Co. has a 12 month low of $80.42 and a 12 month high of $121.90. The stock’s 50-day moving average is $99.55 and its two-hundred day moving average is $94.39.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.